Article Correctness Is Author's Responsibility: Dana-Farber research supports FDA approval for immunotherapy combination in advanced kidney cancer

An immunotherapy agent combined with a tyrosine kinase inhibitor drug whose clinical testing as a first-line treatment in advanced kidney cancer was led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, has become a standard therapy.